- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02316990
China Survey of Stress Ulcer Bleeding in Critically Ill Neurosurgical Patients (SUP)
Stress ulcers or stress-related mucosal disease (SRMD) is defined as "acute superficial inflammation lesions of the gastric mucosa induced when an individual is subject to abnormally elevated physiologic demands."[1] Studies have shown that SRMD occurred in 75%-100% ICU patients[1]. Gastrointestinal bleeding due to SRMD is an important complication in critically ill patients. The frequency of clinically important bleeding ranged from 5.3% to 33%.[2] The mortality in ICU patients with stress related bleeding approaches 50%, which is much higher than the patients without bleeding (9%). [3] In 1999, the American Society of Health-System Pharmacists (ASHP) published guidelines on the use of stress ulcer prophylaxis in medical, surgical, respiratory, and pediatric ICU patients [2]. PPIs and H2RA are widely used in China current clinical practice for the prevention of stress ulcer bleeding. However, there is no epidemiology data to show the risk factors for stress ulcer bleeding and the bleeding rate of Chinese neurosurgical critically ill patients who are usually suffering from brain trauma, cerebral haemorrhage or brain tumour operation. Information is needed to know about the characteristics in Chinese critically ill neurosurgical patients.
Objectives of this Non-Interventional Study Primary
- Primary objective: To estimate the overall incidence of upper gastrointestinal (GI) bleeding in critically ill neurosurgical patients in China.
Main secondary objective
- To estimate the incidence of upper GI bleeding with clinically significant complications in critically ill neurosurgical patients in China.
- To estimate the incidence of any overt upper GI bleeding without clinically significant complications in critically ill neurosurgical patients in China.
- To assess time to upper GI bleeding after a cerebral lesion.
- To investigate potential risk factors associated with upper GI bleeding, and assess how common certain risk factors occurred in upper GI bleeding patients.
- To assess the overall incidence of upper GI bleeding in critically ill patients by different risk factors for upper GI bleeding.
- To investigate the drugs, the route of administration, the doses and the duration commonly used for stress ulcer prophylaxis.
- To investigate the proportion of ICU patients with nasogastric tube, and the duration of nasogastric tube.
(ICU: Intensive care unit PPIs: Proton pump inhibitors H2RA: H2 receptor antagonist)
Study Overview
Status
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Beijing
-
Beijing, Beijing, China
- Research Site
-
-
Fujian
-
Fuzhou, Fujian, China
- Research Site
-
-
Hebei
-
Tangshan, Hebei, China
- Research Site
-
-
Hunan
-
Changsha, Hunan, China
- Research Site
-
-
Jilin
-
Changchun, Jilin, China
- Research Site
-
-
Shandong
-
Jinan, Shandong, China
- Research Site
-
-
Shanghai
-
Shanghai, Shanghai, China
- Research Site
-
-
Shanxi
-
Xi'an, Shanxi, China
- Research Site
-
-
Sichuan
-
Chengdu, Sichuan, China
- Research Site
-
-
Tianjin
-
Tianjin, Tianjin, China
- Research Site
-
-
Zhejiang
-
Hangzhou, Zhejiang, China
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- The subject population that will be included in the NIS are the consecutive discharged patients ≥18 years old who were hospitalized to Neurosurgical departments. Those whose Glasgow Coma Scale (GCS) ≤10[4] within 24 hours of lesion/admission will be defined as critically ill patients. Three kinds of cases will be included: brain trauma critically ill patients, cerebral haemorrhage critically ill patients or postoperative brain tumour critically ill patients.
Exclusion Criteria:
If participating in any clinical trial, the subject cannot take part in this study. Subjects are ineligible if they have below conditions:
- Those who were likely to swallow blood (for example, those with severe facial trauma or epistaxis;
- Patients with previous total gastrectomy;
- Known upper GI lesions that might bleed (e.g., varices, polyps, tumours, etc);
- Evidence of active GI bleeding including oesophageal and gastric variceal bleeding, Peptic Ulcer Disease (PUD)
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
patients ≥18 ,Neurosurgical departments and whose GCS≤10[4]
The subject population that will be included in the NIS are the consecutive discharged patients ≥18 years old who were hospitalized to Neurosurgical departments and whose GCS≤10[4] within 24 hours of lesion/admission.(GCS: Glasgow Coma Scale NIS: Non-Interventional Study ) |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary variable is the overall incidence of upper GI bleeding in critically ill neurosurgical patients
Time Frame: during the first 14 days (up to 14 days) after the cerebral lesion (trauma, haemorrhage or postoperative).
|
during the first 14 days (up to 14 days) after the cerebral lesion (trauma, haemorrhage or postoperative).
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The incidence of upper GI bleeding with clinically significant complications in critically ill neurosurgical patients
Time Frame: during the first 14 days (up to 14 days) after the cerebral lesion (trauma, haemorrhage or postoperative).
|
during the first 14 days (up to 14 days) after the cerebral lesion (trauma, haemorrhage or postoperative).
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- D1843R00056
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stress Ulcers
-
Dr. Morten Hylander MøllerRigshospitalet, Denmark; Copenhagen Trial Unit, Center for Clinical Intervention...CompletedGastrointestinal Bleeding | Stress UlcersDenmark, Netherlands, Switzerland, Norway, Finland, United Kingdom
-
University of CreteCompletedIschemic Foot Ulcers
-
Azidus BrasilSuspended
-
Medical University of South CarolinaCompletedVenous Ulcers | Leg Ulcers | Varicose UlcersUnited States
-
Nordsjaellands HospitalSkane University Hospital; ReapplixCompletedDiabetic Malleoli Ulcers | Malleoli UlcersDenmark, Sweden
-
Lohmann & RauscherCompletedSurgical Wound | Venous Leg Ulcer | Pressure Ulcer | Skin Graft | Arterial Ulcers | Diabetic UlcersPoland
-
Oneness Biotech Co., Ltd.Taipei Veterans General Hospital, Taiwan; Taipei Medical University Shuang...RecruitingVenous Leg Ulcers (VLU)Taiwan
-
Molnlycke Health Care ABCompletedVenous Leg Ulcers | Mixed Leg UlcersFrance, Germany, Netherlands, Czech Republic
-
Skingenix, Inc.Completed
-
University of TurkuUnknown